{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:58:53Z","timestamp":1791089933347,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cytomegalovirus (CMV) has been a major cause of morbidity and mortality after allogeneic stem cell transplantation (SCT). The importance of the recipient's serologic status is paramount. However, the importance of the donor's serologic status in CMV-seropositive recipients is controversial. We analyzed the influence of the donor's CMV status in a large cohort of patients. A total of 7018 patients seropositive for CMV reported to the European Group for Blood and Marrow Transplantation (EBMT) were included; 5910 patients had undergone HLA-identical sibling SCT and 1108 patients had undergone unrelated donor SCT. Univariate and multivariate proportional hazards models were constructed for survival, event-free survival, transplant-related mortality, and relapse incidence. Patients receiving grafts from CMV-seropositive HLA-identical sibling donors had the same survival as patients grafted from seronegative donors (hazard ratio [HR], 1.04; P = .37; 95% confidence interval [CI], 0.95-1.14). However, unrelated donor stem cell (SC) transplant recipients receiving grafts from CMV-seropositive donors had an improved 5-year survival (35% versus 27%; HR = 0.8; P = .006), an improved event-free survival (30% versus 22%; HR = 0.8; P = .01), and a reduced transplant-related mortality (49% versus 62%; HR = 0.7; P &amp;lt; .001). There was no influence on the relapse incidence. The effects of donor CMV status remained in multivariate analyses. The effect of donor status was different among different disease categories. In patients with chronic myelogenous leukemia (CML), T-cell depletion abrogated the beneficial effect of donor status, suggesting that the effect is mediated through transfer of donor immunity. Our data suggest that donor CMV status influences outcome of unrelated SCT. For a CMV-seropositive patient, a seropositive donor might be preferable. (Blood. 2003;102:4255-4260)<\/jats:p>","DOI":"10.1182\/blood-2002-10-3263","type":"journal-article","created":{"date-parts":[[2003,8,26]],"date-time":"2003-08-26T00:48:58Z","timestamp":1061858938000},"page":"4255-4260","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":209,"title":["Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis"],"prefix":"10.1182","volume":"102","author":[{"given":"Per","family":"Ljungman","sequence":"first","affiliation":[{"name":"From the Department of Hematology, Huddinge University Hospital, Stockholm, Sweden; Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands; Department of Medicine, University Hospital, Tu\u0308bingen, Germany; Department of Hematology, Ospedale San Martino, Genova, Italy; Department of Haematology\/Oncology, University of Leipzig, Germany; and Department of Hematology, Ho\u0302pital Henri Mondor, Creteil, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Brand","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Huddinge University Hospital, Stockholm, Sweden; Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands; Department of Medicine, University Hospital, Tu\u0308bingen, Germany; Department of Hematology, Ospedale San Martino, Genova, Italy; Department of Haematology\/Oncology, University of Leipzig, Germany; and Department of Hematology, Ho\u0302pital Henri Mondor, Creteil, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Huddinge University Hospital, Stockholm, Sweden; Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands; Department of Medicine, University Hospital, Tu\u0308bingen, Germany; Department of Hematology, Ospedale San Martino, Genova, Italy; Department of Haematology\/Oncology, University of Leipzig, Germany; and Department of Hematology, Ho\u0302pital Henri Mondor, Creteil, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Frassoni","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Huddinge University Hospital, Stockholm, Sweden; Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands; Department of Medicine, University Hospital, Tu\u0308bingen, Germany; Department of Hematology, Ospedale San Martino, Genova, Italy; Department of Haematology\/Oncology, University of Leipzig, Germany; and Department of Hematology, Ho\u0302pital Henri Mondor, Creteil, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Huddinge University Hospital, Stockholm, Sweden; Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands; Department of Medicine, University Hospital, Tu\u0308bingen, Germany; Department of Hematology, Ospedale San Martino, Genova, Italy; Department of Haematology\/Oncology, University of Leipzig, Germany; and Department of Hematology, Ho\u0302pital Henri Mondor, Creteil, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cordonnier","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Huddinge University Hospital, Stockholm, Sweden; Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands; Department of Medicine, University Hospital, Tu\u0308bingen, Germany; Department of Hematology, Ospedale San Martino, Genova, Italy; Department of Haematology\/Oncology, University of Leipzig, Germany; and Department of Hematology, Ho\u0302pital Henri Mondor, Creteil, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222025948500_REF1","doi-asserted-by":"crossref","unstructured":"Goodrich J, Bowden R, Fisher L, Keller C, Schoch G, Meyers J. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118: 173-178.","DOI":"10.7326\/0003-4819-118-3-199302010-00003"},{"key":"2020021222025948500_REF2","doi-asserted-by":"crossref","unstructured":"Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet. 1994;343: 749-753.","DOI":"10.1016\/S0140-6736(94)91835-X"},{"key":"2020021222025948500_REF3","doi-asserted-by":"crossref","unstructured":"Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118: 179-184.","DOI":"10.7326\/0003-4819-118-3-199302010-00004"},{"key":"2020021222025948500_REF4","doi-asserted-by":"crossref","unstructured":"Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86: 2815-2820.","DOI":"10.1182\/blood.V86.7.2815.2815"},{"key":"2020021222025948500_REF5","doi-asserted-by":"crossref","unstructured":"Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor\/recipient serostatus acute GVHD and CMV disease. Bone Marrow Transplant. 1998;21: 597-605.","DOI":"10.1038\/sj.bmt.1701139"},{"key":"2020021222025948500_REF6","doi-asserted-by":"crossref","unstructured":"Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood. 1992;80: 1358-1364.","DOI":"10.1182\/blood.V80.5.1358.1358"},{"key":"2020021222025948500_REF7","doi-asserted-by":"crossref","unstructured":"Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95: 2240-2245.","DOI":"10.1182\/blood.V95.7.2240"},{"key":"2020021222025948500_REF8","doi-asserted-by":"crossref","unstructured":"Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153: 478-488.","DOI":"10.1093\/infdis\/153.3.478"},{"key":"2020021222025948500_REF9","doi-asserted-by":"crossref","unstructured":"Grob JP, Grundy JE, Prentice HG, et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet. 1987;1: 774-776.","DOI":"10.1016\/S0140-6736(87)92800-5"},{"key":"2020021222025948500_REF10","doi-asserted-by":"crossref","unstructured":"Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation. 1998;66: 1330-1334.","DOI":"10.1097\/00007890-199811270-00012"},{"key":"2020021222025948500_","doi-asserted-by":"crossref","unstructured":"Meyers J, Flournoy N, Thomas E. Nonbacterial pneumonia after allogeneic marrow transplantation: review of ten years' experience. Rev Infect Dis. 1982;4: 1119-1131.","DOI":"10.1093\/clinids\/4.6.1119"},{"key":"2020021222025948500_REF12","doi-asserted-by":"crossref","unstructured":"Zaia JA, Forman SJ. Cytomegalovirus infection in the bone marrow transplant recipient. Infect Dis Clin North Am. 1995;9: 879-900.","DOI":"10.1016\/S0891-5520(20)30707-8"},{"key":"2020021222025948500_REF13","unstructured":"Bacigalupo A, Tedone E, Sanna MA, et al. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Haematologica. 1992;77: 507-513."},{"key":"2020021222025948500_REF14","doi-asserted-by":"crossref","unstructured":"Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant. 1997;19: 241-248.","DOI":"10.1038\/sj.bmt.1700637"},{"key":"2020021222025948500_REF15","doi-asserted-by":"crossref","unstructured":"Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol. 2001;112: 228-236.","DOI":"10.1046\/j.1365-2141.2001.02519.x"},{"key":"2020021222025948500_REF16","doi-asserted-by":"crossref","unstructured":"Wagner JA, Ross H, Hunt S, et al. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation. 1995;60: 1473-1477.","DOI":"10.1097\/00007890-199560120-00018"},{"key":"2020021222025948500_REF17","doi-asserted-by":"crossref","unstructured":"Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999;340: 1462-1470.","DOI":"10.1056\/NEJM199905133401903"},{"key":"2020021222025948500_REF18","doi-asserted-by":"crossref","unstructured":"Humar A, Wood S, Lipton J, et al. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants. Clin Infect Dis. 1998;26: 606-610.","DOI":"10.1086\/514569"},{"key":"2020021222025948500_REF19","doi-asserted-by":"crossref","unstructured":"Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98: 2043-2051.","DOI":"10.1182\/blood.V98.7.2043"},{"key":"2020021222025948500_REF20","doi-asserted-by":"crossref","unstructured":"Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood. 1999;93: 467-480.","DOI":"10.1182\/blood.V93.2.467"},{"key":"2020021222025948500_","doi-asserted-by":"crossref","unstructured":"Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood. 2000;96: 2299-2303.","DOI":"10.1182\/blood.V96.6.2299"},{"key":"2020021222025948500_REF22","doi-asserted-by":"crossref","unstructured":"Heitger A, Greinix H, Mannhalter C, et al. Requirement of residual thymus to restore normal T-cell subsets after human allogeneic bone marrow transplantation. Transplantation. 2000;69: 2366-2373.","DOI":"10.1097\/00007890-200006150-00026"},{"key":"2020021222025948500_REF23","doi-asserted-by":"crossref","unstructured":"de Vries E, van Tol MJ, van den Bergh RL, et al. Reconstitution of lymphocyte subpopulations after paediatric bone marrow transplantation. Bone Marrow Transplant. 2000;25: 267-275.","DOI":"10.1038\/sj.bmt.1702141"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/13\/4255\/1693547\/h82403004255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/13\/4255\/1693547\/h82403004255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T10:10:11Z","timestamp":1623319811000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/13\/4255\/17439\/Donor-CMV-serologic-status-and-outcome-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,15]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2003,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-10-3263","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,15]]}}}